On the basis of such assessments of therapeutic effects, some studies have proposed the concept of using novel bispecific antibodies to target PD‐L1 and CTLA‐4 immune checkpoints in order to produce synergistic anti‐tumor effects. This evidence concerns the gene CTLA4 and neoplasm.